Surufatinib, approved in China in late 2020 for the treatment of well-differentiated extrapancreatic neuroendocrine tumors (NETs), selectively inhibits VEGFR 1, 2, and 3, FGFR1, and CSF-1R, offering a targeted approach to managing these tumors [25]. This evidence concerns the gene CSF1R and neuroendocrine neoplasm.